Education
About Us
Working with TipRanks
Follow Us
Skye Bioscience, Inc. (SKYE)
:SKYE
Earnings Data
Report Date
Nov 06, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of Skye Bioscience's progress. While the company showcased significant advancements in its clinical trials and financial stability, it also faced challenges with increased R&D expenses and a substantial net loss. The strategic developments and promising preclinical data are positive highlights, but the enrollment challenges in the extension study indicate areas needing attention.Company Guidance
Phase IIa CBeyond Study Progress
The Phase IIa CBeyond study for nimacimab is advancing as planned, on budget, and ahead of schedule. Enrollment was completed in February, and the 26-week visit for the last patient is projected to occur very shortly. The Data Safety Monitoring Committee has reviewed the study four times with no recommendations for changes.
Promising Preclinical Data
The combination of nimacimab and a suboptimal tirzepatide dose demonstrated 44% vehicle-adjusted weight loss in a preclinical study. Nimacimab alone showed 21.5% weight loss, and it reduced rebound weight gain when used as a maintenance therapy post-incretin treatment.
Financial Stability
Skye ended the second quarter with $48.6 million in cash and cash equivalents, expecting to fund operations and key clinical milestones through at least Q1 2027. Research and development expenses increased, primarily due to contract manufacturing and clinical trial costs.
Strategic Developments and Hiring
Skye expanded its team to 20 employees, with key hires in regulatory affairs, quality, clinical operations, and CMC. The deliberate scaling aims to minimize downtime between clinical trials and support nimacimab's advancing development activities.
SKYE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SKYE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $3.55 | $3.52 | -0.85% |
May 08, 2025 | $1.79 | $1.81 | +1.12% |
Mar 20, 2025 | $1.89 | $2.25 | +19.05% |
Nov 07, 2024 | $5.44 | $5.71 | +4.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Skye Bioscience, Inc. (SKYE) report earnings?
Skye Bioscience, Inc. (SKYE) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).
What is Skye Bioscience, Inc. (SKYE) earnings time?
Skye Bioscience, Inc. (SKYE) earnings time is at Nov 06, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SKYE EPS forecast?
SKYE EPS forecast for the fiscal quarter 2025 (Q3) is -0.3.